Bristol-Myers Opdivo Study in Glioblastoma Multiforme Misses Primary Endpoint
09 Mai 2019 - 2:10PM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Thursday said a phase 3 study
of its cancer drug Opdivo to treat a form of the aggressive tumor
glioblastoma multiforme didn't meet its primary endpoint of overall
survival.
The New York biopharmaceutical company said the study evaluated
Opdivo plus radiation compared with the chemotherapy drug
temozolomide plus radiation in patients with newly diagnosed
O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma
multiforme.
Opdivo's safety profile was consistent with previous studies in
solid tumors, Bristol-Myers said.
Bristol-Myers said it remains committed to studying the
potential of immunotherapy to address glioblastoma multiforme, the
most common and most aggressive type of primary malignant tumor of
the central nervous system.
Opdivo, which harnesses the body's immune system to fight
cancer, has been approved for use in several types of cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 09, 2019 07:55 ET (11:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
